Moloney murine leukemia virus decay mediated by retroviral reverse transcriptase degradation of genomic RNA

Virology

Volumn 380, Issue 1, 2008, Pages 91-98

  Casali, Monica ^a,c   Zambonelli, Carlo ^b   Goldwasser, Jonathan ^a   Vu, Halong N ^a   Yarmush, Martin L ^a,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD UNIVERSITY   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

Gamma retrovirus; Moloney murine leukemia virus; RNA and protein stability; Viral reverse transcriptase; Virus decay

Indexed keywords

RNA DIRECTED DNA POLYMERASE; VIRUS PROTEIN; VIRUS RNA;

ARTICLE; CIRCULAR DICHROISM; CONTROLLED STUDY; DRUG ACTIVITY; EMBRYO; MOLONEY LEUKEMIA ONCOVIRUS; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA DEGRADATION; RNA STABILITY; RNA STRUCTURE; SITE DIRECTED MUTAGENESIS; TIME; VIRUS INFECTIVITY; VIRUS RECOMBINANT;

GENOME, VIRAL; MOLONEY MURINE LEUKEMIA VIRUS; RETROVIRIDAE; REVERSE TRANSCRIPTION; RNA, VIRAL; RNA-DIRECTED DNA POLYMERASE; VIRAL PROTEINS;

MAMMALIA; MOLONEY MURINE LEUKEMIA VIRUS;

EID: 52049093876     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2008.07.011     Document Type: Article

References (57)

1. Aiuti A., Slavin S., Aker M., Ficara F., Deola S., Mortellaro A., Morecki S., Andolfi G., Tabucchi A., Carlucci F., Marinello E., Cattaneo F., Vai S., Servida P., Miniero R., Roncarolo M.G., and Bordignon C. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296 5577 (2002) 2410-2413
2. Ausar S.F., Espina M., Brock J., Thyagarayapuran N., Repetto R., Khandke L., and Middaugh C.R. High-throughput screening of stabilizers for respiratory syncytial virus: identification of stabilizers and their effects on the conformational thermostability of viral particles. Hum. Vaccin. 3 3 (2007) 94-103
3. Ausar S.F., Rexroad J., Frolov V.G., Look J.L., Konar N., and Middaugh C.R. Analysis of the thermal and pH stability of human respiratory syncytial virus. Mol. Pharm. 2 6 (2005) 491-499
4. Barquinero J., Eixarch H., and Perez-Melgosa M. Retroviral vectors: new applications for an old tool. Gene Ther. 11 Suppl 1 (2004) S3-S9
5. Beer C., Meyer A., Muller K., and Wirth M. The temperature stability of mouse retroviruses depends on the cholesterol levels of viral lipid shell and cellular plasma membrane. Virology 308 1 (2003) 137-146
6. Ben-Artzi H., Zeelon E., Gorecki M., and Panet A. Double-stranded RNA-dependent RNase activity associated with human immunodeficiency virus type 1 reverse transcriptase. Proc. Natl. Acad. Sci. U. S. A. 89 3 (1992) 927-931
7. Blain S.W., and Goff S.P. Nuclease activities of Moloney murine leukemia virus reverse transcriptase. Mutants with altered substrate specificities. J. Biol. Chem. 268 31 (1993) 23585-23592
8. Cantor, and Schimmel. Biophysical Chemistry." 2 - Part II: Techniques For The Study Of Biological Structure And Function (1980), Freeman 3 vols
9. Cavazzana-Calvo M., Hacein-Bey S., de Saint Basile G., Gross F., Yvon E., Nusbaum P., Selz F., Hue C., Certain S., Casanova J.L., Bousso P., Deist F.L., and Fischer A. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288 5466 (2000) 669-672
10. Chuck A.S., Clarke M.F., and Palsson B.O. Retroviral infection is limited by Brownian motion. Hum. Gene Ther. 7 13 (1996) 1527-1534
11. Cosset F.L., Takeuchi Y., Battini J.L., Weiss R.A., and Collins M.K. High-titer packaging cells producing recombinant retroviruses resistant to human serum. J. Virol. 69 12 (1995) 7430-7436
12. D'Souza V., and Summers M.F. Structural basis for packaging the dimeric genome of Moloney murine leukaemia virus. Nature 431 7008 (2004) 586-590
13. Daly G., and Chernajovsky Y. Recent developments in retroviral-mediated gene transduction. Mol. Ther. 2 5 (2000) 423-434
14. Danos O., and Mulligan R.C. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc. Natl. Acad. Sci. U. S. A. 85 17 (1988) 6460-6464
15. Davis H.E., Morgan J.R., and Yarmush M.L. Polybrene increases retrovirus gene transfer efficiency by enhancing receptor-independent virus adsorption on target cell membranes. Biophys. Chem. 97 2-3 (2002) 159-172
16. Davis H.E., Rosinski M., Morgan J.R., and Yarmush M.L. Charged polymers modulate retrovirus transduction via membrane charge neutralization and virus aggregation. Biophys. J. 86 2 (2004) 1234-1242
17. Dhawan J., Pan L.C., Pavlath G.K., Travis M.A., Lanctot A.M., and Blau H.M. Systemic delivery of human growth hormone by injection of genetically engineered myoblasts. Science 254 5037 (1991) 1509-1512
18. Fu W., Dang Q., Nagashima K., Freed E.O., Pathak V.K., and Hu W.S. Effects of Gag mutation and processing on retroviral dimeric RNA maturation. J. Virol. 80 3 (2006) 1242-1249
19. Fu W., and Rein A. Maturation of dimeric viral RNA of Moloney murine leukemia virus. J. Virol. 67 9 (1993) 5443-5449
20. Garret, and Grisham (1995). Nucleotides and Nucleic Acids. In "Biochemistry" (S.c Publishing, Ed.),pp. 199-202.
21. Goff S.P. Retroviral reverse transcriptase: synthesis, structure, and function. J. Acquir. Immune Defic. Syndr. 3 8 (1990) 817-831
22. Gordon E.M., and Anderson W.F. Gene therapy using retroviral vectors. Curr. Opin. Biotechnol. 5 6 (1994) 611-616
23. Hanenberg H., Xiao X.L., Dilloo D., Hashino K., Kato I., and Williams D.A. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat. Med. 2 8 (1996) 876-882
24. Hibbert C.S., and Rein A. Preliminary physical mapping of RNA-RNA linkages in the genomic RNA of Moloney murine leukemia virus. J. Virol. 79 13 (2005) 8142-8148
25. Jacobo-Molina A., and Arnold E. HIV reverse transcriptase structure-function relationships. Biochemistry 30 26 (1991) 6351-6356
26. Kohl N.E., Emini E.A., Schleif W.A., Davis L.J., Heimbach J.C., Dixon R.A., Scolnick E.M., and Sigal I.S. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. U. S. A. 85 13 (1988) 4686-4690
27. Kohn D.B., Sadelain M., Dunbar C., Bodine D., Kiem H.P., Candotti F., Tisdale J., Riviere I., Blau C.A., Richard R.E., Sorrentino B., Nolta J., Malech H., Brenner M., Cornetta K., Cavagnaro J., High K., and Glorioso J. American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol. Ther. 8 2 (2003) 180-187
28. Kotani H., Newton III P.B., Zhang S., Chiang Y.L., Otto E., Weaver L., Blaese R.M., Anderson W.F., and McGarrity G.J. Improved methods of retroviral vector transduction and production for gene therapy. Hum. Gene Ther. 5 1 (1994) 19-28
29. Kwon Y.J., and Peng C.A. High-yield retroviral production using a temperature-modulated two-stage operation. Biotechnol. Bioeng. 90 3 (2005) 365-372
30. Le Doux J.M., Davis H.E., Morgan J.R., and Yarmush M.L. Kinetics of retrovirus production and decay. Biotechnol. Bioeng. 63 6 (1999) 654-662
31. Le Doux J.M., Morgan J.R., Snow R.G., and Yarmush M.L. Proteoglycans secreted by packaging cell lines inhibit retrovirus infection. J. Virol. 70 9 (1996) 6468-6473
32. Le Doux J.M., Morgan J.R., and Yarmush M.L. Removal of proteoglycans increases efficiency of retroviral gene transfer. Biotechnol. Bioeng. 58 1 (1998) 23-34
33. Le Doux J.M., Morgan J.R., and Yarmush M.L. Differential inhibition of retrovirus transduction by proteoglycans and free glycosaminoglycans. Biotechnol. Prog. 15 3 (1999) 397-406
34. Lim D., Gregorio G.G., Bingman C., Martinez-Hackert E., Hendrickson W.A., and Goff S.P. Crystal structure of the moloney murine leukemia virus RNase H domain. J. Virol. 80 17 (2006) 8379-8389
35. Mason J.M., Guzowski D.E., Goodwin L.O., Porti D., Cronin K.C., Teichberg S., and Pergolizzi R.G. Human serum-resistant retroviral vector particles from galactosyl (alpha1-3) galactosyl containing nonprimate cell lines. Gene Ther. 6 8 (1999) 1397-1405
36. Merten O.W., Cruz P.E., Rochette C., Geny-Fiamma C., Bouquet C., Goncalves D., Danos O., and Carrondo M.J. Comparison of different bioreactor systems for the production of high titer retroviral vectors. Biotechnol. Prog. 17 2 (2001) 326-335
37. Miller D.G., Adam M.A., and Miller A.D. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol. Cell Biol. 10 8 (1990) 4239-4242
38. Mitani K., Wakamiya M., and Caskey C.T. Long-term expression of retroviral-transduced adenosine deaminase in human primitive hematopoietic progenitors. Hum. Gene Ther. 4 1 (1993) 9-16
39. Murti K.G., Bondurant M., and Tereba A. Secondary structural features in the 70S RNAs of Moloney murine leukemia and Rous sarcoma viruses as observed by electron microscopy. J. Virol. 37 1 (1981) 411-419
40. Pages J.C., and Bru T. Toolbox for retrovectorologists. J. Gene Med. 6 Suppl 1 (2004) S67-S82
41. Paul R.W., Morris D., Hess B.W., Dunn J., and Overell R.W. Increased viral titer through concentration of viral harvests from retroviral packaging lines. Hum. Gene Ther. 4 5 (1993) 609-615
42. Pensiero M.N., Wysocki C.A., Nader K., and Kikuchi G.E. Development of amphotropic murine retrovirus vectors resistant to inactivation by human serum. Hum. Gene Ther. 7 9 (1996) 1095-1101
43. Pham L., Ye H., Cosset F.L., Russell S.J., and Peng K.W. Concentration of viral vectors by co-precipitation with calcium phosphate. J. Gene Med. 3 2 (2001) 188-194
44. Poryvaev V.D. A thermodynamic analysis of oxidative inactivation of influenza virus and lipid peroxidation of viral envelope lipids. Vopr. Virusol. 40 6 (1995) 273-276
45. Poryvaev V.D., Viatkina T.G., Ryzhikov A.B., Sergeev A.N., and Iagofarov S.R. Effect of components of virus-containing allantoic fluid on the stability of influenza virus during storage. Vopr. Virusol. 41 3 (1996) 126-129
46. Poryvaev V.D., and Zykova N.A. The effect of conditions of storage and composition of viral material on lipid peroxidation of the viral envelope and inactivation of the influenza virus. Vopr. Virusol. 40 2 (1995) 62-65
47. Price J., Turner D., and Cepko C. Lineage analysis in the vertebrate nervous system by retrovirus-mediated gene transfer. Proc. Natl. Acad. Sci. U. S. A. 84 1 (1987) 156-160
48. Reeves L., and Cornetta K. Clinical retroviral vector production: step filtration using clinically approved filters improves titers. Gene Ther. 7 23 (2000) 1993-1998
49. Relph K., Harrington K., and Pandha H. Recent developments and current status of gene therapy using viral vectors in the United Kingdom. BMJ 329 7470 (2004) 839-842
50. Riggin C.H., Bondurant M., and Mitchell W.M. Physical properties of Moloney murine leukemia virus high-molecular-weight RNA: a two subunit structure. J. Virol. 16 6 (1975) 1528-1535
51. Robbins P.D., and Ghivizzani S.C. Viral vectors for gene therapy. Pharmacol. Ther. 80 1 (1998) 35-47
52. Roe T., Reynolds T.C., Yu G., and Brown P.O. Integration of murine leukemia virus DNA depends on mitosis. Embo. J. 12 5 (1993) 2099-2108
53. Takeuchi Y., Porter C.D., Strahan K.M., Preece A.F., Gustafsson K., Cosset F.L., Weiss R.A., and Collins M.K. Sensitization of cells and retroviruses to human serum by (alpha 1-3) galactosyltransferase. Nature 379 6560 (1996) 85-88
54. Traktman P., and Baltimore D. Protease bypass of temperature-sensitive murine leukemia virus maturation mutants. J. Virol. 44 3 (1982) 1039-1046
55. Vu H.N., Ramsey J.D., and Pack D.W. Engineering of a stable retroviral gene delivery vector by directed evolution. Mol. Ther. (2007)
56. Witte O.N., and Baltimore D. Relationship of retrovirus polyprotein cleavages to virion maturation studied with temperature-sensitive murine leukemia virus mutants. J. Virol. 26 3 (1978) 750-761
57. Zhang H., Duan L.X., Dornadula G., and Pomerantz R.J. Increasing transduction efficiency of recombinant murine retrovirus vectors by initiation of endogenous reverse transcription: potential utility for genetic therapies. J. Virol. 69 6 (1995) 3929-3932